Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CNCR Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisDividendHeadlinesHoldingsRatingsShort InterestTrends About Range Cancer Therapeutics ETF (NASDAQ:CNCR) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get CNCR alerts:Sign Up Key Stats Today's Range$13.25▼$13.5250-Day Range$27.45▼$32.2552-Week Range$25.99▼$35.82Volume1,335 shsAverage Volume6,668 shsMarket Capitalization$15.84 millionAssets Under Management$11.20 millionDividend Yield2.16%Net Expense Ratio0.79%Aggregate RatingModerate Buy ETF OverviewThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.Read More… This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Range Cancer Therapeutics ETF ExpensesTypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.79%0.57%0.55%0.49%0.52%Other Expenses0.00%0.30%0.49%0.41%0.53%Total Expense0.79%0.70%0.71%0.63%0.71%Fee Waiver0.00%-0.45%-0.52%-0.32%-0.57%Net Expense0.79%0.61%0.61%0.56%0.59% Receive CNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address CNCR ETF News HeadlinesBuy Rating Affirmed for TScan Therapeutics Amid Positive Developments in TCR-T Cell Therapy SpaceOctober 12, 2024 | markets.businessinsider.comSummit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC SubpopulationSeptember 9, 2024 | seekingalpha.comThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. November 21, 2024 | Porter & Company (Ad)Range Oncology Therapeutics Index ETF (CNCR)August 15, 2024 | finance.yahoo.comTango Therapeutics Shuts Early-Stage Cancer Study Due To Liver ToxicityMay 23, 2024 | msn.comIntensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology DrugMay 14, 2024 | seekingalpha.comSee More Headlines CNCR ETF - Frequently Asked Questions What other stocks do shareholders of Range Cancer Therapeutics ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Range Cancer Therapeutics ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Fund Details IssuerExchange Traded Concepts Fund NameRange Cancer Therapeutics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CNCR Inception Date10/13/2015 Fund ManagerDenise M. Krisko WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkRange Cancer Therapeutics Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings77 Fund Statistics Assets Under Management$11.20 million Average Daily Volume$3,394.30 Discount/Premium-0.05% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorExchange Traded Concepts, LLC CustodianU.S. Bank, N.A. DistributorQuasar Distributors, LLC Transfer AgentU.S. Bank, N.A. TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest1,700 shs Miscellaneous Outstanding Shares1,180,000Beta1.36 Creation Unit50,000 Creation Fee$150.00 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Top 10 CNCR HoldingsMonte Rosa Therapeutics (NASDAQ:GLUE)Holding Weight: 2.13%ImmunityBio (NASDAQ:IBRX)Holding Weight: 1.97%Zymeworks (NYSE:ZYME)Holding Weight: 1.83%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 1.82%Exelixis (NASDAQ:EXEL)Holding Weight: 1.80%Mersana Therapeutics (NASDAQ:MRSN)Holding Weight: 1.80%Arcellx (NASDAQ:ACLX)Holding Weight: 1.74%Bristol-Myers Squibb (NYSE:BMY)Holding Weight: 1.65%Ginkgo Bioworks (NYSE:DNA)Holding Weight: 1.65%Genelux (NASDAQ:GNLX)Holding Weight: 1.63%Full Holdings DetailsCNCR Sector ExposureCNCR Industry Exposure This page (NASDAQ:CNCR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
